Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
The author thank Jeff Meyer and Marie Hollinger for their help as graduate assistants.
- 2.
White Book – U.S. Healthcare: A Mess Central Planning in Capitalism's Backyard; May 2005, pp. 9-14, 6p <Business Source Complete> http://search.ebscohost.com.ezproxy.tamu.edu:2048/login.aspx?direct=true&db=bth&AN=18535978&site=bsi-live
- 3.
Pharmaceutical Industry Profile 2007. Pharmaceutical Research and Manufacturers of America. 2007 < http://www.phrma.org/files/Profile%202007.pdf> Page 25
- 4.
Agovina, Teresa. “Global Pharmaceutical Sales Up 7 Pct.” Associated Press. 2007 Mar 20 <http://www.forbes.com/feeds/ap/2007/03/20/ap3535773.html>
- 5.
Pharmaceutical Industry Profile 2007. Pharmaceutical Research and Manufacturers of America. 2007 <http://www.phrma.org/files/Profile%202007.pdf>
- 6.
White Book - U.S. Healthcare: A Mess Central Planning in Capitalism's Backyard; May2005, pp. 9-14, 6p <Business Source Complete> http://search.ebscohost.com.ezproxy.tamu.edu:2048/login.aspx?direct=true&db=bth&AN=18535978&site=bsi-live
- 7.
Economic Intelligence Unit. “Regional and Country Data.” 3/27/2006 <Business Source Complete> http://search.ebscohost.com.ezproxy.tamu.edu:2048/login.aspx?direct=true&db=bth&AN=20396424&site=bsi-live
- 8.
http://www.jpma.or.jp/english/library/index.html, Pharmaceutical Industry Profile 2007. Pharmaceutical Research and Manufacturers of America. 2007 <http://www.phrma.org/files/Profile%202007.pdf>
- 9.
Pharmaceutical Industry Profile 2007. Pharmaceutical Research and Manufacturers of America. 2007 <http://www.phrma.org/files/Profile%202007.pdf>
- 10.
Pharmaceutical Industry Profile 2007. Pharmaceutical Research and Manufacturers of America. 2007 <http://www.phrma.org/files/Profile%202007.pdf>
References
Agarwal, S., S. Desai, M.H. Holcomb, A. Oberoi. 2001. Unlocking the Value in Big Pharma. McKinsey Quarterly 2 65–73.
Berndt, E.R. 2006. The United States’ Experience with Direct-to-Consumer Advertising of Prescription Drugs: What have we Learned? Chapter 9, in Sloan, F.A., C.-R. Hsieh, Promoting and Coping with Pharmaceutical Innovation: An International Perspective. Cambridge University Press, Cambridge MA.
Caciotti, J., B. Shew. 2006. Pharma’s Next Top Model. Pharmaceutical Executive 26(3) 82–86.
Chintagunta, P.K., R. Desiraju. 2005. Strategic Pricing and Detailing Behavior in International Markets. Marketing Science 24(1) 67–80.
Danzon P., S. Nicholson, N.S. Pereira. 2005. Productivity in Pharmaceutical-Biotechnology R&D: the Role of Experience and Alliances. Journal of Health Economics 24 317–339.
Dekimpe, M.G., D.M. Hanssens. 1999. Sustained Spending and Persistent Response: A New Look at Long-Term Marketing Profitability. Journal of Marketing Research 36(4) 397–412.
DiMasi, J.A., R.W. Hansen, H.G. Grabowski. 2003. The Price of Innovation: New Estimates of Drug Development Costs.Journal of Health Economics 151–185.
Ding, M., J. Eliashberg. 2002. Structuring the New Product Development Pipeline. Management Science 48(3) 343–63.
Ding, M., J. Eliashberg. 2008. A Dynamic Competitive Forecasting Model Incorporating Dyadic Decision-Making. Management Science 54(4) 820–834.
Fischer, M., V. Shankar, M. Clement. 2005. Can a Late Mover Use International Market Entry Strategy to Challenge the Pioneer? MSI Report No. 05-004, 25–48. Marketing Science Institute, Cambridge: MA.
Gatignon, H., E. Anderson, K. Helsen. 1989. Competitive Reactions to Market Entry: Explaining Interfirm Differences. Journal of Marketing Research 26(1) 44–55.
Gatignon, H., B. Weitz, P. Bansal. 1990. Brand Introduction Strategies and Competitive Environments. Journal of Marketing Research 27(4) 390–401.
Grabowski, H., J. Vernon. 1990. A New Look at the Returns and Risks to Pharmaceutical R&D. Management Science 36(7) 804–821.
Grabowski, H., J. Vernon, J.A. Dimasi. 2002. Returns on Research and Development for 1990s New Drug Introductions. Pharmacoeconomics 20(3) 11–29.
Grewal, R., M. Ding, J. Liechty. 2006. Evaluating New Product Portfolio Strategies. Working Paper. Penn State University, PA.
Gönül, F.F., K. Srinivasan. 2001. Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior. Journal of Marketing 65(3) 79–90.
Hahn, M., S. Park, L. Krishnamurthi, A. Zoltners. 1994. Analysis Of New Product Diffusion Using A Four Segment Trial-Repeat Model. Marketing Science 13(3) 224–247.
Hoover’s .2006. Hoover’s Index.
IMS Health 2006. IMS Retail Drug Monitor. December.
Kalaignanam, Kartik, V. Shankar, R. Varadarajan. 2007. To End or Extend: An Empirical Analysis of Determinants of New Product Development Alliance Terminations. Working Paper. Texas A&M University, TX.
Lee, J. 2003. Innovation and Strategic Divergence: An Empirical Study of the U.S. Pharmaceutical Industry from 1920 to 1960. Management Science 49(2) 143–159.
Lilien, G.L., A.G. Rao, S. Kalish. 1981. Bayesian Estimation And Control Of Detailing Effort In A Repeat Purchase Diffusion Environment. Management Science 27(5) 493–506.
Manchanda, P., P.K. Chintagunta. 2004. Responsiveness of Physician Prescription Behavior to Sales force Effort: An Individual Level Analysis. Marketing Letters 15(2–3) 129–145.
Manchanda, P., P.E. Rossi, P.K. Chintagunta. 2004. Response Modeling with Nonrandom Marketing-Mix Variables. Journal of Marketing Research 41(4) 467–478.
Manchanda, P., P.E. Rossi, P.K. Chintagunta. 2004. Response Modeling with Nonrandom Marketing-Mix Variables. Journal Of Marketing Research 41(4) 467–478.
Manchanda, P., E. Honka. 2005. The Effects and Role of Direct-to-Physician Marketing in the Pharmaceutical Industry: An Integrative Review. Yale Journal of Health Policy, Law and Ethics 2 785–822.
Mantrala, M.K., P. Sinha, A. Zoltners. 1994. Structuring A Multiproduct Sales Quota-Bonus Plan for A Heterogeneous Sales Force: A Practical Model-Based Approach. Marketing Science 13(2) 121–44.
Mizik, N., R. Jacobson. 2004. Are Physicians 'Easy Marks'?: Quantifying the Effects of Detailing and Sampling on New Prescriptions. Management Science 50(12) 1704–1715.
Montgomery, D.B., A.J. Silk 1972. Estimating Dynamic Effects of Market Communications Expenditures. Management Science 18(10) B485–B501.
Narayanan, S., P. Manchanda, P.K. Chintagunta. 2005. Temporal Differences in the Role of Marketing Communication in New Product Categories. Journal of Marketing Research 42(3) 278–290.
Narayanan, S., R. Desiraju, P.K. Chintagunta. 2004. Return on Investment Implications for Pharmaceutical Promotional Expenditures: The Role of Marketing-Mix Interactions. Journal of Marketing 68(4) 90–105.
Neslin, S.A. 2001. ROI Analysis of Pharmaceutical Promotion (RAPP): An Independent Study. Association of Medical Publications, (accessed October 26, 2005), [available at http://www.rxpromoroi.org/rappl/]
PhRMA .2007. Pharmaceutical Industry Profile Pharmaceutical Research and Manufacturers of America, http://www.phrma.org/files/Profile%202007.pdf.
Rangaswamy, A., L. Krishnamurthi. 1991. Response Function Estimation Using the Equity Estimator. Journal of Marketing Research 28(1) 72–83.
Rangaswamy, A., P. Sinha, A. Zoltners. 1990. An Integration Model-Based Approach for Sales Force Structuring. Marketing Science 9(4) 279–98.
Rao, A.G., M. Yamada. 1988. Forecasting With A Repeat Purchase Diffusion Model. Management Science 34(6) 734–752.
Shankar, V. 1997. Pioneers’ Marketing Mix Reactions to Entry in Different Competitive Games Structures: Theoretical Analysis and Empirical Illustration. Marketing Science 16(4) 271–293.
Shankar, V. 1999. New Product Introduction and Incumbent Response Strategies: Their Interrelationship and the Role of Multimarket Contact. Journal of Marketing Research 36(3) 327–344.
Shankar, V. 2008. The Role of Product Life Cycle and Market Dominance in Marketing Expenditures of Products. Working Paper. Texas A&M University, TX.
Shankar, V., G.S. Carpenter, L. Krishnamurthi. 1998. Late Mover Advantage: How Innovative Late Entrants Outsell Pioneers. Journal of Marketing Research 35(1) 54–70.
Shankar, V., G.S. Carpenter, L. Krishnamurthi 1999. The Advantages of Entry in the Growth Stage of the Product Life Cycle: An Empirical Analysis. Journal of Marketing Research 36(2) 269–276.
Singh, A., P. Henske 2003. Has the Pharmaceutical Blockbuster Model Gone Bust? Bain & Company Report.
Sorescu, A.B., R.K. Chandy, J.C. Prabhu. 2003. Sources and Financial Consequences of Radical Innovation: Insights from Pharmaceuticals. Journal of Marketing, 67(4) 82–102.
Trombetta, B. 2007. Industry Audit. Pharmaceutical Executive, September.
Wierenga, B., G.H. van Bruggen, R. Staelin. 1999. The Success of Marketing Management Support Systems. Marketing Science 18(3) 196–207.
Wosinska, M. 2005. Direct-to-Consumer Advertising and Drug Therapy Compliance. Journal of Marketing Research 42(3) 323–332.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Shankar, V. (2008). Strategic Marketing Decision Models for the Pharmaceutical Industry. In: Wierenga, B. (eds) Handbook of Marketing Decision Models. International Series in Operations Research & Management Science, vol 121. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-78213-3_14
Download citation
DOI: https://doi.org/10.1007/978-0-387-78213-3_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-78212-6
Online ISBN: 978-0-387-78213-3
eBook Packages: Business and EconomicsBusiness and Management (R0)